Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2001-10-09
2003-04-15
Henley, III, Raymond J. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S275000
Reexamination Certificate
active
06548507
ABSTRACT:
The present invention relates to the use of sodium channel antagonists for the treatment of diseases mediated by, or exacerbated by, neuronal apoptosis, in particular sensory neuronal apoptosis.
BACKGROUND TO THE INVENTION
EP-0021121-A discloses a group of 3,5-diamino-6-(substituted phenyl)-1,2,4-triazines which are active in the treatment of central nervous system (CNS) disorders, for example in the treatment of epilepsy. One such triazine is 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine which is alternatively called lamotrigine.
EP-0372934-A discloses pyrimidine compounds useful in the treatment of CNS disorders. Example 14 of this application discloses 5-(2,3-dichlorophenyl)-6-trifluoromethyl-2,4-diaminopyrimidine, Example 18 of EP-0372934-A discloses 2,4-diamino-5-(2,3-dichlorophenyl)-6-fluoromethyl pyrimidine and Example 45 discloses 5-(2,6-dichlorophenyl)-6-methyl-2,4-diaminopyrimidine.
WO 97/09317 discloses the R(−) enantiomer of Example 18 of EP0372934-A, R(−)-2,4-diamino-5-(2,3-dichlorophenyl)-6-fluoromethyl pyrimidine, substantially free of the corresponding S(+)enantiomer, ie the compound of formula (I):
and acid addition salts thereof. This compound is also known as 4030W92.
WO98/38174 discloses pyrazine derivatives useful in the treatment of CNS disorders such as epilepsy, ie the compounds of formula (II):
wherein
R
1
is selected from the group consisting of phenyl substituted by one or more halogen atoms, naphthyl and naphthyl substituted by one or more halogen atoms;
R
2
is selected from the group consisting of —NH
2
and —NHC(═O)R
a
;
R
3
is selected from the group consisting of —NR
b
R
c
, —NHC(═O) R
a
and hydrogen;
R
4
is selected from the group consisting of hydrogen, —C
1-4
alkyl (preferably methyl), —C
1-4
alkyl (preferably methyl) substituted by one or more halogen atoms, —CN, —CH
2
OH, —CH
2
OR
d
and —CH
2
S(O)
x
R
d
;
wherein
R
a
represents C
1-4
alkyl or C
3-7
cycloalkyl, and
R
b
and R
c
, which may be the same or different, are selected from hydrogen and C
1-4
alkyl, or together with the nitrogen atom to which they are attached, form a 6-membered nitrogen containing heterocycle, which heterocycle can be further substituted with one or more C
1-4
alkyl;
R
d
is selected from C
1-4
alkyl or C
1-4
alkyl substituted by one or more halogen atoms;
x is an integer zero, one or two;
and pharmaceutically acceptable derivatives thereof;
with the proviso that R
1
does not represent;
when R
2
is —NH
2
, and both R
3
and R
4
are hydrogen. Particularly preferred is 2,6-diamino-3-(2,3,5-trichlorophenyl)pyrazine and pharmaceutically acceptable derivatives thereof.
WO99/32462 (PCT/EP98/08273) relates to a triazine compound which is useful in the treatment of central nervous system (CNS) diseases and disorders, ie the compound 5-amino-6-[2,3,5-trichlorophenyl]-1,2,4-triazine and pharmaceutically acceptable derivatives thereof.
WO00/12488 relates to carboxamide derivatives of pyrazine compounds such as those disclosed in WO98/38174 above, in particular 5-carboxamido-2,6-diamino-3-(2,3,5-trichlorophenyl)pyrazine.
The compounds of EP-0021121-A, EP-0372934-A, WO 97/09317, WO98/38174 WO99/32462 and WO00/12488 are sodium channel antagonists and therefore inhibit glutamate release.
Other sodium ion channel blockers include local anaesthetics/anti-dysrhythmics such as: lidocaine, mexilitine, ropivacaine, levobupivacaine; anti-convulsants such as: oxcarbazepine, topiramate, rufinamide, Co-102862, NW-1015; anti-ischaemics such as: sipatrigine, BIIR-561, BIII-890 and RS100642 and the analgesics such as: RS132943, details for which are all available from public databases such as Pharmaprojects.
It has been shown that the sodium channel antagonist, lamotrigine can prevent motorneuronal apoptotic cell death after neonatal axotomy: Casanovas A. et al Neuroscience Vol.71 No2 pp313-325 1996.
SUMMARY OF THE INVENTION
This invention relates to a parallel finding of much greater medical significance, that as a result of their ability to prevent neuronal apoptosis, sodium channel antagonists have a disease modifying effect and serve to halt or delay (slow down) the progression of disease as opposed to merely treating the symptoms of disease. For example, in the case of chronic pain, the sodium channel antagonists are able to halt or delay the underlying process which is causing the pain as well as ease the pain as demonstrated by behavioural testing. Thereby sodium channel antagonists can alter disease states in particular pain states mediated by sensory neuronal apoptosis. The ability to halt or delay the progression of disease states such as certain pain states, neurodegenerative diseases and inflammation, provides a significant breakthrough in the management of these otherwise poorly treated conditions.
Diseases mediated by, or exacerbated by neuronal apoptosis in particular sensory neuronal apoptosis, include: pain states, such as chronic pain states, following nerve insult due to, for example, injury or infection ie pain states associated with tissue damage; neurodegenerative diseases such as multiple sclerosis and Parkinson's disease; and inflammation. Sodium channel antagonists are of use in the treatment of these diseases and are also of use in delaying or halting the progression of these diseases.
It has previously been reported (see for example WO98/38186) that a deficiency of oxygen, for example in the region of a cerebral infarct, causes abnormally high concentrations of glutamic acid to be released. This leads to an overstimulation of excitatory amino acid receptors, eg NMDA receptors, resulting in the degeneration and death of neurones by way of a mechanism known as excitotoxicity. This process has been implicated in the pathophysiology of various neurodegenerative conditions. Sodium channel antagonists are known to inhibit glutamate release and therefore prevent the degeneration and death of neurones due to excitotoxicity.
However, neuronal apoptosis which occurs as a result of nerve damage is unrelated to nerve death due to excitotoxicity and it is not dependent on glutamic acid concentration. “Apoptosis” is a form of programmed cell death. A report from the Cell Death Nomenclature Committee (Apoptosis, Necrosis or Oncosis, Levin S. Toxicological Sciences 41 155-156 1998) defines the prelethal steps that follow cellular injury as apoptosis or oncosis (but not necrosis). Apoptosis is characterised by cytoplasmic shrinkage and karyorrhexis (The Pathways of Cell Death: Oncosis, Apoptosis and Necrosis Trump B. F. et al Toxicological Pathology 25 (1) 82-88 (1997)—chromatin is fragmented and packaged in bits of cell membrane. This shows up as densely coloured apoptotic bodies when visualised using a nuclear stain under the light microscope. Using electron microscopy the cytosol appears dense, endoplasmic reticulum may be dilated and mitochondria are condensed. Blebs in the cytoplasm will typically contain organelles. Breaks in the DNA that lead to karyorrhexis can be identified using gel electrophoresis or TUNEL staining but this alone is no longer considered adequate as cells stained positive using TUNEL, do not necessarily have the characteristics of apoptosis when studied at the electron microscopy level. The fluorescent nuclear stain Hoechst 33342 and light microscopic analysis is now considered the best technique. The most striking gross morphological characteristic is cell shrinkage.
As mentioned above, agents which prevent neuronal apoptosis have a disease modifying effect and serve to halt or delay the progression of disease.
The invention accordingly provides, in a first aspect the use of sodium channel antagonists in the treatment of diseases mediated by, or exacerbated by, neuronal apoptosis.
In a further aspect, the invention provides the use of sodium channel antagonists as disease modifying agents in diseases mediated by, or exacerbated by, neuronal apoptosis.
There is also provided as a further aspect of the invention the use of sodium channel antagonists in the preparation of a medicament f
Bountra Charanjit
Nobbs Malcolm Stuart
Doppenbrock Bonnie L.
Henley III Raymond J.
SmithKline Beecham Corporation
LandOfFree
Medical use does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Medical use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Medical use will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3038278